Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Proteostasis Therapeutics

Proteostasis Therapeutics (NASDAQ: PTI) develops disease-modifying therapeutics for diseases of protein processing. It provides clinical-stage novel small molecule therapies to treat the cause of cystic fibrosis. The company was founded in 2007 and is based in Boston, Massachusetts.

Headquarters Location

200 Technology Square 4th Floor

Boston, Massachusetts, 02139,

United States




Proteostasis Therapeutics Patents

Proteostasis Therapeutics has filed 41 patents.

The 3 most popular patent topics include:

  • proteins
  • ion channels
  • cystic fibrosis
patents chart

Application Date

Grant Date


Related Topics




Proteins, Heat shock proteins, Protein structure, Molecular biology, Human proteins


Application Date


Grant Date



Related Topics

Proteins, Heat shock proteins, Protein structure, Molecular biology, Human proteins



Latest Proteostasis Therapeutics News

Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla

Jun 28, 2023

Seattle, Washington, UNITED STATES SEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the appointment of Kim Drapkin and Scott Dylla, Ph.D. to its Board of Directors. Ms. Drapkin will join the company’s audit and compensation committees and Dr. Dylla will join the compensation committee. “Kim and Scott’s extensive strategic, financial and clinical expertise, paired with their proven track records of leading commercial and development-stage biopharmaceutical companies, make them strong additions to our Board of Directors,” said Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta. “I am looking forward to working closely with them as we enter this exciting time in Kineta’s evolution as a clinical stage public company, creating new opportunities for cancer patients with unmet needs, the company and our shareholders.” Kim Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Most recently, Ms. Drapkin was the CFO at Jounce Therapeutics, Inc., a position she held since the company’s inception, playing a key role in building Jounce’s financial infrastructure. Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim CFO for numerous early-stage biotechnology companies. Previously, she was the CFO at EPIX Pharmaceuticals, Inc. and also spent ten years in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals, Inc. Her career began in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Ms. Drapkin served as a member of Yumanity Therapeutics, Inc.’s board of directors since the completion of the merger of Proteostasis Therapeutics, Inc. and Yumanity, Inc. and previously served on the board of directors of Proteostasis. She currently serves on the board of directors of Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) and Imugene Limited (ASX: IMU), where she chairs the audit committee at both companies. Ms. Drapkin holds a B.S. in accounting from Babson College. Scott Dylla, Ph.D. is currently an entrepreneur, investor and advisor of early-stage biotech companies. Dr. Dylla currently serves as the chairman of the board of Chimera Bioengineering and as a board member of 3D Bio Holdings LLC. Previously, Dr. Dylla served as a Vice President of Research and Development at AbbVie Inc. (NYSE: ABBV), functioning also as the Chief Scientific Officer of the Stemcentrx division in South San Francisco, CA until July 2018. He co‐founded Stemcentrx in 2008, growing the company to 160 employees with numerous clinical assets launched by 2016 when the company was acquired by AbbVie for $6.2 billion. Prior to founding Stemcentrx in 2008, Dr. Dylla was one of the first scientists at OncoMed Pharmaceuticals, Inc., where he spearheaded the identification and characterization of solid tumor cancer stem cells (CSC), and led seminal work to identify colorectal CSC and demonstrate their resistance to chemotherapy. Dr. Dylla received his B.S. in Biochemistry & Molecular Biology from the University of Minnesota, Duluth, a Master’s Degree in Molecular Pathobiology from the University of Alabama, Birmingham, and his doctorate in Immunology & Cancer Biology from the University of Minnesota. Dr. Dylla trained as a postdoctoral scholar at Stanford University with stem cell pioneer, Dr. Irving Weissman, and in 2005 was recognized by the British Council as one of eight outstanding young US‐based researchers in the field of stem cell biology. About Kineta Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. For more information on Kineta, please visit , and follow Kineta on Twitter , LinkedIn and Facebook . Cautionary Statements Regarding Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” and other similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Kineta’s current beliefs, expectations and assumptions regarding the future of Kineta’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including, but not limited to: the adequacy of Kineta’s capital to support its future operations (including its ability to complete the second tranche of the previously disclosed contemplated private placement in the third quarter of 2023) and its ability to successfully initiate and complete clinical trials; the difficulty in predicting the time and cost of development of Kineta’s product candidates; Kineta’s plans to research, develop and commercialize its current and future product candidates, including, but not limited to, KVA12123; the timing and anticipated results of Kineta’s planned pre-clinical studies and clinical trials and the risk that the results of Kineta’s pre-clinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials; the timing of the availability of data from Kineta’s clinical trials; the timing of any planned investigational new drug application or new drug application; the risk of cessation or delay of any ongoing or planned clinical trials of Kineta or its collaborators; the clinical utility, potential benefits and market acceptance of Kineta’s product candidates; Kineta’s commercialization, marketing and manufacturing capabilities and strategy; developments and projections relating to Kineta’s competitors and its industry; the impact of government laws and regulations; the timing and outcome of Kineta’s planned interactions with regulatory authorities; Kineta’s ability to protect its intellectual property position; Kineta’s estimates regarding future revenue, expenses, capital requirements and need for additional financing; the intended use of proceeds from the registered direct offering completed in April 2023; and those risks set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 31, 2023, and Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023, as well as discussions of potential risks, uncertainties and other important factors in Kineta’s subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Except as required by law, Kineta undertakes no obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise. FOR FURTHER INFORMATION, PLEASE CONTACT: Kineta, Inc. :

Proteostasis Therapeutics Frequently Asked Questions (FAQ)

  • When was Proteostasis Therapeutics founded?

    Proteostasis Therapeutics was founded in 2007.

  • Where is Proteostasis Therapeutics's headquarters?

    Proteostasis Therapeutics's headquarters is located at 200 Technology Square, Boston.

  • What is Proteostasis Therapeutics's latest funding round?

    Proteostasis Therapeutics's latest funding round is IPO.

  • How much did Proteostasis Therapeutics raise?

    Proteostasis Therapeutics raised a total of $122.6M.

  • Who are the investors of Proteostasis Therapeutics?

    Investors of Proteostasis Therapeutics include Novartis Venture Funds, F-Prime Capital, Sanofi-Genzyme BioVentures, New Enterprise Associates, Rock Springs Capital and 4 more.

  • Who are Proteostasis Therapeutics's competitors?

    Competitors of Proteostasis Therapeutics include CellCentric, Carmot Therapeutics, DiscoveryBioMed, InterveXion Therapeutics, Actimis Pharmaceuticals and 7 more.


Compare Proteostasis Therapeutics to Competitors

Lead Therapeutics

LEAD Therapeutics, Inc. is a chemistry-driven drug discovery company focused on delivering novel and differentiated small molecule pre-IND candidates against clinically validated therapeutic targets by leveraging the best of the US and China. Headquartered in the San Francisco Bay Area, LEAD Therapeutics is led by an experienced small molecule drug discovery team with proven track records in the pharmaceutical and biotech industries. The company plans to carry out the majority of its discovery research activities in China.

Active Pass Pharmaceuticals

Active Pass is a Canadian biotechnology company that is engaging in genomic-based drug discovery and is developing drugs that inhibit ABC transporters. ABC or (ATP binding cassette) is a term that describes the interconnected group of molecular engines or pumps that function as a transportation system which moves compounds across the biological membranes. These ABCs are very closely associated with human diseases like Alzheimer's disease, diabetes, asthma, and hypertension. The Active Pass management team is an accomplished group with experience in many aspects of drug discovery and development. Besides employing full time pharmaceutical development professionals, Active Pass has made wise use of a group of several key partnerships with different pharmaceutical groups. The company cultivates these partnerships in order to access new capabilities or expertise to advance the company's own technologies. More specifically, these partnerships include the Vaccines and Infectious Diseases Organization as well as the National Institute of Health). The company hopes to add new personnel to cover emerging areas of emphasis like clinical and regulatory affairs, business development and finance as they grow.


Priaxon is a research company focusing on drug discovery for small molecule therapeutics.

InterveXion Therapeutics

InterveXion Therapeutics is a drug discovery and development company focused on antibody-based therapies for treating human disease. The company are developing monoclonal antibodies to treat substance abuse from PCP and methamphetamine.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that focuses on biochemical reagents, assays, and peptides within the academic research and pharmaceutical development sectors. The company offers a range of products and services including antibodies, proteins, biochemical reagents, and custom synthesis services, all designed to support scientific research and development. Echelon Biosciences primarily serves the academic research and pharmaceutical development industries. It is based in Salt Lake City, Utah.


Kalypsys is a drug discovery company using a cellular ultra high-throughput system to carry out massive drug screening in cellular models of human disease and toxicology.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.